President Donald Trump has moved to intensify pressure on the pharmaceutical industry by ordering 100% tariffs on branded drugs imported into the United States unless manufacturers either agree to government drug pricing arrangements or commit to producing their medicines domestically. The measure opens a new front in the administration’s effort to cut prescription costs while also pushing more manufacturing back onto U.S. soil.
The policy is significant because it combines trade pressure, industrial policy, and drug pricing in a single framework. It does not hit all parts of the market equally. Major drugmakers that already negotiated pricing deals with the government have carved out protections, while generic medicines remain temporarily exempt. That leaves many small and mid sized companies in a more exposed position, raising fears that the new system could deepen inequalities within the sector.
The result is a highly selective tariff regime that rewards companies with scale, manufacturing flexibility, and enough negotiating power to strike deals with Washington. For the rest of the industry, especially firms with narrower product portfolios, the order creates a more difficult and expensive operating environment at a time when pricing pressure is already intensifying.
A tariff designed to force pricing and manufacturing change
Under the order, the United States will impose a 100% tariff on patented or branded medicines that are imported and not protected by pricing agreements or domestic production commitments. Large pharmaceutical companies have 120 days to announce plans that would allow them to avoid the full penalty, while smaller companies are being given 180 days.
The administration is also offering a lower tariff path for companies willing to shift production into the United States. Drugmakers that move manufacturing onshore can face a reduced 20% tariff instead of the full 100% rate. Those that both build in the U.S. and sign most favored nation pricing agreements with the Department of Health and Human Services can avoid tariffs entirely.
This structure makes the policy more than a simple import tax. It is a bargaining tool designed to push companies toward two goals at once: cheaper U.S. drug prices and a stronger domestic manufacturing base. That combination reflects Trump’s broader approach of using trade leverage to force strategic decisions from industries seen as politically and economically important.
Big drugmakers gain protection while smaller firms face risk
The new regime is likely to create an uneven playing field across the pharmaceutical sector. The administration has already reached agreements with 17 drugmakers, with 13 finalized and four still under negotiation. Those arrangements give major companies tariff protection for billions of dollars worth of branded products and, in many cases, buy them time through multi year exemptions.
That is one reason industry groups representing smaller firms are warning that the order could create a two tiered structure. While larger global manufacturers often have diversified portfolios, stronger balance sheets, and greater room to relocate or negotiate, smaller and mid sized biotech and specialty firms may lack the same flexibility. For them, a sudden jump in import costs could be much harder to absorb.
The Midsized Biotech Alliance of America has already argued that the policy risks favoring companies that were first to secure pricing deals with the administration, leaving others at a structural disadvantage. In practice, that means the order could reshape competition inside the industry as much as it reshapes trade flows.
Exemptions soften the immediate blow
Not every drug category will be hit right away. Generic medicines are exempt from tariffs for at least one year, an important carve out given that more than 90% of medicines sold in the United States are generics. Orphan drugs, veterinary medicines, and certain specialty products are also exempt when they come from countries with relevant trade arrangements or meet urgent public health needs.
Country specific treatment also adds nuance to the policy. Branded medicines produced in the European Union, Japan, South Korea, and Switzerland face a reduced 15% tariff because of existing trade arrangements, while the United Kingdom is covered by a separate tariff deal. Those lower rates suggest the administration is trying to balance pressure on drugmakers with the practical limits of disrupting key international supply relationships too abruptly.
Even with those exemptions, the signal from Washington is unmistakable. The White House is prepared to use tariffs not just against foreign products in general, but against specific segments of the pharmaceutical market in order to influence both pricing behavior and corporate investment decisions.
The order reflects a broader drug pricing fight
The policy also fits into Trump’s continuing push to force U.S. prescription prices closer to those paid in other wealthy countries. American patients often pay far more for branded medicines than consumers in comparable developed markets, and the administration has been using its most favored nation pricing strategy to attack that gap directly. The tariff order gives that effort a new enforcement mechanism.
For the administration, the logic is politically powerful. If companies want access to the U.S. market without punitive tariffs, they must either lower prices, build locally, or both. For the industry, however, the move creates difficult trade offs around investment, margins, and future product strategy. Firms that do not already have agreements in place now face a compressed timeline to negotiate, restructure supply chains, or absorb far higher costs.
That means the executive order is likely to have effects well beyond import pricing. It may influence where future plants are built, how companies prioritize launches, and which parts of the pharmaceutical sector gain or lose competitive ground. In trying to lower drug prices and bring production home, Washington may end up redrawing parts of the industry’s structure at the same time.
